Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.80 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.63 |
| ▸ | PGR | P06401 | 1/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19701102 | 0.94 | NR1H4 (0.71) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL17883440 | 0.94 | NR1H4 (0.80) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL17883458 | 0.90 | NR1H4 (0.80) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL273529 | 0.89 | NR1H4 (1.00) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL29880856 | 0.89 | NR1H4 (1.00) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL19260855 | 0.89 | NR1H4 (0.80) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL19701136 | 0.88 | NR1H4 (0.71) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL29880689 | 0.88 | NR1H4 (0.84) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL3738573 | 0.88 | NR1H4 (0.84) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL30726135 | 0.87 | NR1H4 (0.78) | NR1H4ESR1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017143134-A1 | FXR MODULATORS AND METHODS OF THEIR USE | ALIOS BIOPHARMA, INC. (US) | 2017-08-24 | — | — | WO | claimed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3237419-B1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-10793577-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20190211026-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2019-07-11 | — | — | US | disclosed |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| WO-2017143134-A1 | FXR MODULATORS AND METHODS OF THEIR USE | ALIOS BIOPHARMA, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793577-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | NR1H4 59/4885ESR1 989/4885NR3C1 362/4885 |
| US-20170355704-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | NR1H4 59/4885ESR1 989/4885NR3C1 362/4885 |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | NR1H4 59/4885ESR1 989/4885NR3C1 362/4885 |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | NR1H4 59/4885ESR1 989/4885NR3C1 362/4885 |
| US-20190211026-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | NR1H4 59/4885ESR1 989/4885NR3C1 362/4885 |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | NR1H4 59/4885ESR1 989/4885NR3C1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.